<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320648">
  <stage>Registered</stage>
  <submitdate>28/09/2009</submitdate>
  <approvaldate>1/10/2009</approvaldate>
  <actrnumber>ACTRN12609000850279</actrnumber>
  <trial_identification>
    <studytitle>Combined corticosteroid and long-acting beta-agonist versus corticosteroid for moderate/severe chronic obstructive pulmonary disease. A double blind, randomized, multicenter, phase III study.</studytitle>
    <scientifictitle>In adults with Chronic Obstructive Pulmonary Disease (COPD), is corticosteroid combined with long-acting beta-agonist effective in forced expiratory volume in one second (FEV1) values, as compared to corticosteroid?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>COPD (Chronic obstructive pulmonary disease)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Two arms: 
1)Fluticasone 500 micrograms +Formoterol 12 micrograms, twice a day, for 12 weeks; capsule for inhalation
2)Fluticasone 500 micrograms, twice a day, for 12 weeks; capsule for inhalation</interventions>
    <comparator>Fluticasone 500 micrograms, twice a day, for 12 weeks; capsule for inhalation</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>forced expiratory volume in one second
(FEV1) measures (comparing randomization visit and last visit)
test: spirometry</outcome>
      <timepoint>screening visit, randomization visit and last visit (12 week)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>forced vital capacity (FVC) measures  (comparing randomization visit and last visit)
test: spirometry</outcome>
      <timepoint>screening visit, randomization visit and last visit (12 week)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>rescue medication (utilization) -Short acting Beta-agonist</outcome>
      <timepoint>all visits, except for the screening visit (diary card)
Frequency of visits: Baseline and once monthly for 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>peak flow variation using a peak flow meter</outcome>
      <timepoint>All visits, except for the screening visit
Frequency of visits: Baseline and once monthly for 12 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>moderate or severe COPD according to GOLD (Global Initiative for Chronic Obstructive Lung Disease)

smoker or former smoker</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Hospitalization due to COPD up to 4 weeks before screening visit

Subjects who have required treatment with oral corticosteroids, anti-leukotriene, immunoglobulins, beta-blockers, digitalis, itraconazole  2 months prior to Visit 1</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>30/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>136</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ach√© Laboratories</primarysponsorname>
    <primarysponsoraddress>Rodovia Dutra km 222,2
Guarulhos, State of Sao Paulo
Brazil
CEP (ZIP) 07034-904</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ache Laboratories</fundingname>
      <fundingaddress>Rodovia Dutra km 222,2
Guarulhos, State of Sao Paulo
Brazil
CEP (ZIP) 07034-904</fundingaddress>
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In adults with Chronic Obstructive Pulmonary Disease (COPD) the study will compare the efficacy of a corticosteroid combined with long-acting beta-agonist effective in forced expiratory volume in one second (FEV1) values, as compared to corticosteroid. The hypothesis will consider the superiority of the combination therapy.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>15/06/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Fabio Ikedo</name>
      <address>Rodovia Dutra km 222,2
CEP 07034-904
Guarulhos
Sao Paulo
Brazil</address>
      <phone>55-11-26088181</phone>
      <fax />
      <email>fabio.ikedo@ache.com.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fabio Ikedo</name>
      <address>Rodovia Dutra km 222,2
CEP 07034-904
Guarulhos
Sao Paulo
Brazil</address>
      <phone>55-11-26088181</phone>
      <fax />
      <email>fabio.ikedo@ache.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>